{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:46:39Z","timestamp":1790930799556,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T00:00:00Z","timestamp":1236038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background: <\/jats:bold> Antibodies to soluble liver antigen (SLA)\/liver pancreas (LP) are generally considered as highly specific diagnostic markers of type 1 auto\u2010immune hepatitis (AIH\u20101), and are particularly useful in patients without conventional antibodies. However, the presence of anti\u2010SLA\/LP in type 2 auto\u2010immune hepatitis (AIH\u20102), primary sclerosing cholangitis (PSC) and hepatitis C has recently been reported. The aim was thus to describe the characteristics of anti\u2010SLA\/LP\u2010positive patients in the largest series reported to date.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> Sera were selected from the period between 1998 and 2005, based on the presence of antibodies to SLA\/LP detected by two methods. The clinical status of patients was determined from their medical records.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> Eighty\u2010one anti\u2010SLA\/LP\u2010positive patients with available clinical data were included: 89% (72\/81) had a diagnosis of AIH\u20101, including 10 (12%) associated with cholestatic diseases (primary biliary cirrhosis in seven cases and PSC in three cases). Six patients (7%) suffered from another liver disease: hepatitis C (<jats:italic>n<\/jats:italic>=3) and drug\u2010induced hepatitis (<jats:italic>n<\/jats:italic>=3). No specific diagnosis was made in three patients.<\/jats:p><jats:p><jats:bold>Conclusions: <\/jats:bold> Antibodies to SLA\/LP are of a major diagnostic value for AIH\u20101, including paediatric forms and overlap syndromes with cholestatic diseases, but are not found in association with anti\u2010liver\/kidney\/microsome type 1 or antibodies to liver cytosol type 1. They are rarely present in other liver diseases such as hepatitis C and drug\u2010induced hepatitis.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2009.01986.x","type":"journal-article","created":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T15:26:18Z","timestamp":1236093978000},"page":"857-864","source":"Crossref","is-referenced-by-count":50,"title":["Significance of antibodies to soluble liver antigen\/liver pancreas: a large French study"],"prefix":"10.1111","volume":"29","author":[{"given":"Violaine","family":"Eyraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chazouilleres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ballot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Poupon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Johanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,6,5]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"1502","article-title":"Autoimmune hepatitis","volume":"120","author":"Manns MP","year":"2001","journal-title":"clinical challenges"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80425-0"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20539"},{"key":"e_1_2_6_5_2","first-page":"998","article-title":"Meeting report","volume":"18","author":"Johnson PJ","year":"1993","journal-title":"International Autoimmune Hepatitis Group"},{"key":"e_1_2_6_6_2","first-page":"929","article-title":"International Autoimmune Hepatitis Group Report","volume":"31","author":"Alvarez F","year":"1999","journal-title":"review of criteria for diagnosis of autoimmune hepatitis"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.20223"},{"key":"e_1_2_6_8_2","first-page":"677","article-title":"Liver autoimmune serology","volume":"41","author":"Vergani D","year":"2004","journal-title":"a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92024-1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90160-E"},{"key":"e_1_2_6_11_2","first-page":"527","article-title":"Relation between autoimmune liver disease and viral hepatitis","volume":"33","author":"Lohse AW","year":"1995","journal-title":"clinical and serological characteristics in 859 patients"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1997.tb00384.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80342-0"},{"key":"e_1_2_6_14_2","first-page":"208","article-title":"Antibodies to soluble liver antigen","volume":"33","author":"Ballot E","year":"2000","journal-title":"an additional marker in type 1 auto-immune hepatitis"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02166-8"},{"key":"e_1_2_6_16_2","first-page":"259","article-title":"Establishment of standardised SLA\/LP immunoassays","volume":"51","author":"Baeres M","year":"2002","journal-title":"specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics"},{"key":"e_1_2_6_17_2","first-page":"77","article-title":"Low frequency of anti\u2010SLA\/LP autoantibodies in Japanese adult patients with autoimmune liver diseases","volume":"21","author":"Miyakawa H","year":"2003","journal-title":"analysis with recombinant antigen assay"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2005.01079.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkm1122"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/0891693021000054101"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/08916930410001702469"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32092"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/0891693021000056712"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/08916930410001686260"},{"key":"e_1_2_6_25_2","first-page":"296","article-title":"Primary biliary cirrhosis\u2013autoimmune hepatitis overlap syndrome","volume":"28","author":"Chazouill\u00e8res O","year":"1998","journal-title":"clinical features and response to therapy"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.4.589"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240201"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.1860080507"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj0600604"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/227680a0"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.76.9.4350"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2007.00289.x"},{"key":"e_1_2_6_33_2","first-page":"831","article-title":"Antibodies to SS\u2010A\/Ro\u201052kD and centromere in autoimmune liver disease","volume":"26","author":"Granito A","year":"2007","journal-title":"a clue to diagnosis and prognosis of primary biliary cirrhosis"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1740-2557-4-2"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(02)00025-9"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(00)80043-2"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01316809"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200609000-00018"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1351.031"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)04410-8"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05479.x"},{"key":"e_1_2_6_42_2","first-page":"893","article-title":"A 10 year follow up study of patients transplanted for autoimmune hepatitis","volume":"52","author":"Duclos\u2010Vall\u00e9e JC","year":"2003","journal-title":"histological recurrence precedes clinical and biochemical recurrence"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2009.01986.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2009.01986.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T18:19:43Z","timestamp":1697134783000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2009.01986.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,5]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1111\/j.1478-3231.2009.01986.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2009.01986.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,5]]}}}